This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Urine VEGF Levels in Very Low Birth Weight (VLBW) Infants

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified August 2008 by Charite University, Berlin, Germany.
Recruitment status was:  Recruiting
Information provided by:
Charite University, Berlin, Germany Identifier:
First received: November 28, 2008
Last updated: NA
Last verified: August 2008
History: No changes posted
VLBW infants are at risk of developing retinopathy of prematurity (ROP). In the first phase of ROP there is a down-regulation of retinal VEGF-expression because of postnatal relative hyperoxia, followed by an upregulation of VEGF mediated through retinal hypoxia, which leads to pathologic vessel formation. VEGF acts through binding to the specific receptor FLT-1, the soluble form sFLT-1 is a specific antagonist of VEGF action. Erythropoietin, given to VLBW infants to prevent anemia, may stimulate VEGF-production in neuronal cells. Currently, there are no data published about VEGF urine-levels in VLBW infants and it is not known, if urine VEGF-levels may serve as a non-invasive marker of ROP-risk. Further shall be investigated, if erythropoietin-therapy increases urine VEGF-levels and if there is a correlation with ROP-development.

Infant, Very Low Birth Weight

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective

Resource links provided by NLM:

Further study details as provided by Charite University, Berlin, Germany:

Primary Outcome Measures:
  • Development of ROP [ Time Frame: 4 months ]

Biospecimen Retention:   Samples Without DNA
Urine samples that are centrifugated to get rid of any cells where stored at -80°C until ELISA is done.

Estimated Enrollment: 160
Study Start Date: August 2008
Estimated Study Completion Date: December 2010
Estimated Primary Completion Date: February 2010 (Final data collection date for primary outcome measure)
VLBW infants with erythropoietin therapy
VLBW infants without erythropoietin therapy.


Ages Eligible for Study:   up to 32 Weeks   (Child)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Pretarem infants of less than 32 weeks of gestation or birth weight below 1500g.

Inclusion Criteria:

  • gestational age < 32 weeks
  • birth weight <1500g

Exclusion Criteria:

  • absent written consent by parents
  • connatal eye malformation
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00799721

Contact: Anke Reinhold, Doctor +49/177/2950661
Contact: Anja Pohl-Schickinger, Doctor +49/30/450566122

Charité Virchow-Hospital Recruiting
Berlin, Germany, 13353
Contact: Anke Reinhold, Doctor   
Sponsors and Collaborators
Charite University, Berlin, Germany
  More Information

Responsible Party: Dr. Anke Reinhold, Charité University Berlin Identifier: NCT00799721     History of Changes
Other Study ID Numbers: EA2/072/08-1
Study First Received: November 28, 2008
Last Updated: November 28, 2008

Keywords provided by Charite University, Berlin, Germany:
very low birth weight infants
retinopathy of prematurity
erythropoietin therapy and risk of ROP

Additional relevant MeSH terms:
Birth Weight
Body Weight
Signs and Symptoms
Epoetin Alfa
Hematinics processed this record on September 20, 2017